Revolution Medicines Ships Experimental Pancreatic Cancer Drug Under Early Access
Revolution Medicines begins expanded access program for daraxonrasib targeting KRAS G12C mutations. FDA submission planned as five-year pancreatic cancer survival…
Editor's Top Picks
NHS Patient Watchdog Abolition Sparks Concerns Over Health Service Accountability
Local councils warn that government plans to abolish NHS patient watchdogs will compromise healthcare accountability. The proposals affect 152 Healthwatch…
Submit Your Paper to GMJ
China’s Infectious Disease Burden Drops by Half Since 2000, But Age-Related Challenges Emerge
China achieved a 50% reduction in infectious disease burden from 2000-2023, but progress was uneven with elderly populations now bearing…
Regional Nerve Block Reduces Opioid Use After Heart Surgery by 25%, Multicentre Trial Shows
A multicentre randomised trial shows bilateral nerve blocks with ropivacaine reduce opioid consumption by 25% after cardiac surgery. The EPOCH…
Mental health interventions show promise for extreme weather trauma recovery
Mental health interventions demonstrate significant effectiveness in reducing PTSD, depression, and anxiety symptoms among people affected by extreme weather events.…
Experimental Drug Shows 96% Viral Suppression in Hepatitis B Clinical Trial
Clinical trial shows experimental drug bepirovirsen achieves 96% viral suppression when combined with standard hepatitis B therapy. Phase III trials…
World’s Largest Longevity Competition Targets Age Reversal Breakthroughs
The XPRIZE Healthspan competition offers $101 million in prizes for age reversal breakthroughs targeting cognitive, muscle, and immune function. Dr.…
Lab-grown brain organoids reveal how to reverse ‘irreversible’ nerve damage
Cambridge researchers used lab-grown brain organoids to discover that human neurons lose regenerative capacity during development, but thyroid hormone therapy…
Phase 3 Trial of Bepirovirsen Shows Promise for Chronic Hepatitis B Treatment
Phase 3 clinical trial results for bepirovirsen, a novel antisense oligonucleotide therapy for chronic hepatitis B, published in The New…
Weight Loss Expert Raises Safety Concerns Over Unregulated GLP-1 ‘Microdoses’
Weight-loss specialist warns about unregulated GLP-1 microdosing trend lacking clinical trial evidence. Long-term safety effects remain unknown for reduced-dose formulations.